A statewide ballot in the US state of Oregon in November could determine whether a program set up in 2003 to offer prescription drug discounts via bulk-purchasing by the State to residents aged 55 or over with low incomes, should be extended to all income levels.
Local media reports indicate that supporters of the plan, which is backed by a coalition of labor unions, consumer groups and health campaigners, have collected more than the 75,630 petition signatures required to force a referendum on the issue.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze